Nexstim Oyj
The answer first
Does Nexstim beat the market?
No, Nexstim has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 12% of Nordic stocks
- Quality43
- Value9
- Trend35
No. 158 of 195 in healthcare
Max for seven days
Follow Nexstim with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Nexstim
Your first answer is free, no account needed.
Do you own Nexstim, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Nexstim and a few more. Free, no card.
Super Stock+44.6%In short
- Nexstim has fallen 35.8% over the past year, including dividends.
- Overall, Nexstim ranks better than 12% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 71.8%. The price is 98.8% below its peak now.
What do analysts think of Nexstim?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 12% of Nordic stocks.
No. 158 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 143 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.47
- Asset turnoverSales divided by everything the company owns0.71
- Return on equityProfit divided by equity+0.6%
- Cash conversionOperating cash flow divided by profit12.70
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 141 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity7.2
- P/SPrice divided by sales5.2
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flow95.3
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 96 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−8.2%
- 6 months+2.7%
- 9 months−23.4%
- 12 months−35.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Nexstim
Nexstim Oyj is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 44 employees.
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb. The company markets and sells its diagnostics systems to universities and teaching hospitals.


See the full analysis of Nexstim.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card